Tags

Type your tag names separated by a space and hit enter

Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.
PLoS One. 2012; 7(5):e36773.Plos

Abstract

BACKGROUND

During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of this observational, non-interventional, prospective single-center study was to evaluate the immunogenicity and tolerability of two intramuscular doses of this novel vaccine in HIV-positive individuals.

METHODS AND FINDINGS

A standard hemagglutination inhibition (HAI) assay was used for evaluation of the seroconversion rate and seroprotection against the pandemic H1N1 strain. In addition, H1N1-specific IgG antibodies were measured using a recently developed ELISA and compared with the HAI results. Tolerability of vaccination was evaluated up to one month after the second dose. A total of 79 HIV-infected adults with an indication for H1N1 vaccination were evaluated. At baseline, 55 of the 79 participants had an HAI titer ≥1:40 and two patients showed a positive IgG ELISA. The seroconversion rate was 31% after the first vaccination, increasing to 41% after the second; the corresponding seroprotection rates were 92% and 83% respectively. ELISA IgG levels were positive in 25% after the first vaccination and in 37% after the second. Among the participants with baseline HAI titers <1:40, 63% seroconverted. Young age was clearly associated with lower HAI titers at baseline and with higher seroconversion rates, whereas none of the seven patients >60 years of age had a baseline HAI titer <1:40 or seroconverted after vaccination. The vaccine was well tolerated.

CONCLUSION

The non-adjuvanted pandemic influenza A (H1N1) vaccine was well tolerated and induced a measurable immune response in a sample of HIV-infected individuals.

Authors+Show Affiliations

Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22629330

Citation

Lagler, Heimo, et al. "Immunogenicity and Tolerability After Two Doses of Non-adjuvanted, Whole-virion Pandemic Influenza a (H1N1) Vaccine in HIV-infected Individuals." PloS One, vol. 7, no. 5, 2012, pp. e36773.
Lagler H, Grabmeier-Pfistershammer K, Touzeau-Römer V, et al. Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. PLoS One. 2012;7(5):e36773.
Lagler, H., Grabmeier-Pfistershammer, K., Touzeau-Römer, V., Tobudic, S., Ramharter, M., Wenisch, J., Gualdoni, G. A., Redlberger-Fritz, M., Popow-Kraupp, T., Rieger, A., & Burgmann, H. (2012). Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. PloS One, 7(5), e36773. https://doi.org/10.1371/journal.pone.0036773
Lagler H, et al. Immunogenicity and Tolerability After Two Doses of Non-adjuvanted, Whole-virion Pandemic Influenza a (H1N1) Vaccine in HIV-infected Individuals. PLoS One. 2012;7(5):e36773. PubMed PMID: 22629330.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. AU - Lagler,Heimo, AU - Grabmeier-Pfistershammer,Katharina, AU - Touzeau-Römer,Veronique, AU - Tobudic,Selma, AU - Ramharter,Michael, AU - Wenisch,Judith, AU - Gualdoni,Guido Andrés, AU - Redlberger-Fritz,Monika, AU - Popow-Kraupp,Theresia, AU - Rieger,Armin, AU - Burgmann,Heinz, Y1 - 2012/05/21/ PY - 2011/11/27/received PY - 2012/04/05/accepted PY - 2012/5/26/entrez PY - 2012/5/26/pubmed PY - 2012/12/18/medline SP - e36773 EP - e36773 JF - PloS one JO - PLoS One VL - 7 IS - 5 N2 - BACKGROUND: During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of this observational, non-interventional, prospective single-center study was to evaluate the immunogenicity and tolerability of two intramuscular doses of this novel vaccine in HIV-positive individuals. METHODS AND FINDINGS: A standard hemagglutination inhibition (HAI) assay was used for evaluation of the seroconversion rate and seroprotection against the pandemic H1N1 strain. In addition, H1N1-specific IgG antibodies were measured using a recently developed ELISA and compared with the HAI results. Tolerability of vaccination was evaluated up to one month after the second dose. A total of 79 HIV-infected adults with an indication for H1N1 vaccination were evaluated. At baseline, 55 of the 79 participants had an HAI titer ≥1:40 and two patients showed a positive IgG ELISA. The seroconversion rate was 31% after the first vaccination, increasing to 41% after the second; the corresponding seroprotection rates were 92% and 83% respectively. ELISA IgG levels were positive in 25% after the first vaccination and in 37% after the second. Among the participants with baseline HAI titers <1:40, 63% seroconverted. Young age was clearly associated with lower HAI titers at baseline and with higher seroconversion rates, whereas none of the seven patients >60 years of age had a baseline HAI titer <1:40 or seroconverted after vaccination. The vaccine was well tolerated. CONCLUSION: The non-adjuvanted pandemic influenza A (H1N1) vaccine was well tolerated and induced a measurable immune response in a sample of HIV-infected individuals. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/22629330/Immunogenicity_and_tolerability_after_two_doses_of_non_adjuvanted_whole_virion_pandemic_influenza_A__H1N1__vaccine_in_HIV_infected_individuals_ L2 - https://dx.plos.org/10.1371/journal.pone.0036773 DB - PRIME DP - Unbound Medicine ER -